New Combination for Patients with Latent Tuberculosis Infection: A Pilot Study

Latent tuberculosis infection (LTBI) is characterized by the presence of immune responses to Mycobacterium tuberculosis without clinical evidence of active TB. LTBI treatment among persons at risk for progression to active disease is an important strategy for TB control and elimination. This prospec...

Full description

Saved in:
Bibliographic Details
Published inJournal of Medical Sciences Vol. 38; no. 6; pp. 252 - 257
Main Authors Te-Yu Lin, Feng-Cheng Liu
Format Journal Article
LanguageChinese
Published 台灣 國防醫學院 01.12.2018
Subjects
isoniazid
isoniazid and rifapentine
Latent tuberculosis infection
MEDLINE
pyrazinamide and HUEXC030
rifampin
Scopus
Online AccessGet full text

Cover

More Information
Summary:Latent tuberculosis infection (LTBI) is characterized by the presence of immune responses to Mycobacterium tuberculosis without clinical evidence of active TB. LTBI treatment among persons at risk for progression to active disease is an important strategy for TB control and elimination. This prospective observational study aimed to compare the incidences of hepatitis and side effects between a new 2‑month combination regimen of isoniazid, rifampin and pyrazinamid (2HRZ) plus excipient and the standard 3‑month regimen of isoniazid and rifapentine (3HP) for LTBI treatment in Taiwan. Materials and Methods: Between January 1, 2017, and December 31, 2017, all patients aged ≥20 years diagnosed LTBI were included in the study. Demographic and baseline laboratory assessment of the patients at diagnosis was collected. Eligible individuals were allocated to the 2‑month regimen comprising HUEXC030, isoniazid, rifampin, and pyrazinamide (2HRZ) or 3‑month regimen with isoniazid and rifapentine (HP). All symptoms and side
ISSN:1011-4564